Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder characterized by a variety of motional and non-motional features (sleep disorder, cognitive dysfunction, autonomic dysfunction, etc.), involving many neuroanatomic areas. Orthostatic hypotension (OH) occurs when cardiovascular adaptive mechanisms fail to compensate for the reduction in venous return when transforming from supine to erect position. It is associated with significantly increased risk of coronary heart disease and stroke incidence. OH, as one of the common autonomic dysfunction symptoms of PD, may cause other symptoms like dizziness, syncope, generalized weakness, muscular pain and so on. OH can result in falls and trauma, which have a strong impact on the quality of life of PD-patients. A degree of damage to the postganglionic sympathetic nerves is suggested as the main cause of OH, with some other factors including age increasing, disease severity or duration. In addition, Vitamin D deficiency, low leptin level and low BMI are also associated with OH in PD patients, according to some recent studies. Removing some predisposing factors and adopting non-pharmacological intervention are the first steps in treatment, while pharmacological treatments can also help with symptomatic relief. But none of them is specifically treating OH in PD patients. Medication management of OH in PD-patients should be guided by specific factors of the patients. Although effective, pharmacological treatments can also lead to or exacerbate supine hypertension (SH) -a common complication of OH, which can complicate the treatment. In this review, we intend to summarize the progress on different aspects of OH in PD-patients including diagnosis, pathogenesis, management and treatment.